Kailera to Present Phase 3 Ribupatide Progress at June 4 Jefferies Conference
KLRA•Kailera will present at the Jefferies Global Healthcare Conference on June 4 at 10:30 am EDT with a live webcast and 90-day replay. The clinical-stage biotech is advancing four obesity candidates, including phase 3 ribupatide once-weekly injectable GLP-1/GIP dual agonist and a once-daily oral GLP-1 receptor agonist.
1. Presentation Details
Kailera’s President and CEO Ron Renaud will speak at the 2026 Jefferies Global Healthcare Conference on June 4 at 10:30 am EDT. Investors can watch the live webcast on Kailera’s website and access a replay archived for 90 days.
2. Obesity Pipeline Overview
Kailera is advancing four clinical-stage obesity therapies. Its lead candidate, ribupatide injection, is in global Phase 3 trials as a once-weekly GLP-1/GIP dual agonist. The company is also developing a once-daily oral GLP-1 receptor agonist, plus additional oral and injectable tri-agonist programs to address diverse treatment needs.
